Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics

Journal of Asthma

Volumn 47, Issue 3, 2010, Pages 340-343

  Ahmad, Zuber ^a   Singh, S K ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Ipratropium; Nonsmoker asthmatics; Salbutamol; Smoker asthmatics

Indexed keywords

IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; SMOKING;

EID: 77951101984     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770900903584456     Document Type: Article

References (16)

1. Barnes PJ. Against the Dutch hypothesis: asthma and chronic obstructive pulmonary diseases are distinct diseases. Am J Respir Crit Care Med 2006; 174:240-243.
2. Thomson NC, Chaudhury R, Livingstone E. Asthma and cigarette smoking. Eur Respir J 2004; 24:822-833.
3. Apostol G, Jacobs D, Tsai A, et al. Early life factors contribute to the decrease in lung function between ages 18 and 40. Am J Respir Crit care Med 2002; 166:166-172.
4. Lang P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15 year follow up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-1200.
5. Peat JK,Woolcock AJ,Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70:171-179.
6. Ulrik CS, Backer V, Dirksen A. A 10 year follow up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax 1992; 47:14-18.
7. R. Chaudhuri, E. Livingston, A. D. McMahon, Jane Lafferty, Iona Fraser, Mark Spears, C. P. McSharry, and N. C. Thomson. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174:127-133.
8. Jindal SK, Kaur SJ. Relative bronchodilatory responsiveness attributable to sympathetic and parasympathetic activity in bronchial asthma. Respiration 1989; 56:16-21.
9. Wimpe JB, Postma DS, Brderveld N, Alting-Hebing D, Van Der Mark TW, Koiler GH. Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. J Allergy Clin Immunol 1992; 89:679-687.
10. Brophy C, Ahmed B, Bayston S, Arnold A, McGiven D, Greenstone M. How long should atrovent be given in acute asthma? Thorax 1998; 53:363-367.
11. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized Ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339:1030-1035.
12. Bruderman I, Aronovsky RC, Smorzik J. A comparative study of various combinations of ipratropium bromide and metaproterenol in allergic asthmatic patients. Chest 1983; 83:208-210.
13. Gross NJ, Skorodin MS. Role of parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311:421-425.
14. Laustiola K, Lassilia R, Kaprio J, Koskenvuo M. Decreased beta-adrenergic receptor density and catecholamine response in male cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Circulation 1988; 78:1234-1240.
15. Allen CJ, Campbell AH. Dose response of ipratropium bromide assessed by two methods. Thorax 1980; 35:137-139.
16. Brown IG, Chan CS,Kelly CA, et al. assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. Thorax 1984; 39:272-276.